|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B显示文摘 | Ming-Hui Li Dan Zhang Lu Zhang Xiao-Jing Qu Yao Lu Ge Shen Shu-Ling Wu Min Chang Ru-Yu Liu Lei-Ping Hu Hong-Xiao Hao Wen-Hao Hua Shu-Jing Song Gang Wan Shun-Ai Liu Yao Xie | 2017 | Chinese Medical Journal2017，，15： | 21 |
| 2 | Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B显示文摘 | Ming-Hui Li Yao Lu Lu Zhang Xing-Yue Wang Chong-Ping Ran Hong-Xiao Hao Dan Zhang Xiao-Jing Qu Ge Shen Shu-Ling Wu Wei-Hua Cao Tian-Lin Qi Ru-Yu Liu Lei-Ping Hu Min Chang Wen-Hao Hua Shun-Ai Liu Gang Wan Yao Xie | 2018 | Chinese Medical Journal2018，，15： | 17 |
| 3 | Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection显示文摘 | Ming-Hui Li Lu Zhang Dan Zhang Wei-Hua Cao Tian-Lin Qi Hong-Xiao Hao Xing-Yue Wang Chong-Ping Ran Xiao-Jing Qu Shun-Ai Liu Yao Lu Ge Shen Shu-Ling Wu Min Chang Ru-Yu Liu Lei-Ping Hu Wen-Hao Hua Gang Wan Jun Cheng Yao Xie | 2018 | Chinese Medical Journal2018，，1： | 16 |
| 4 | HBeAg阳性慢性乙型肝炎核苷(酸)类似物序贯干扰素治疗疗效的相关因素研究显示文摘目的研究HBeAg阳性慢性乙型肝炎(chronic hepatitis B,CHB)患者核苷(酸)类似物[(nucleos(t)ide analogs,NA]序贯干扰素治疗疗效的影响因素。方法NA治疗的HBeAg阳性CHB向PEG-IFNα-2a转换(序贯治疗),二者联合应用3个月后单独应用PEG-IFNα-2a治疗,PEG-IFNα-2a 180μg每周1次皮下注射。监测序贯治疗前(基线)及序贯治疗的第12、24、36、48、及72周的HBsAg、HBeAg和HBV DNA含量。结果共有56例HBeAg阳性的CHB患者入组,其中5例(8.9%)获得HBsAg消失/血清学转换,获得组基线HBsAg含量显著低于非获得组(2.750 lg IU/ml vs 3.699 lg IU/ml,t=0.955,P=0.000);序贯治疗的第12、24、36、48周两组HBsAg下降幅度差异均有统计学意义(0.913 vs 0.149,2.847 vs 0.189,4.378 vs 0.248,4.587 vs 0.274,lg IU/ml)(t=-2.950、P=0.040;t=-8.732、P=0.009;t=-8.483、P=0.001;t=-8.214,P=0.003)。11例(19.6%)获得HBeAg消失/血清学转换,获得组基线HBeAg含量低于非获得患者(1.217 lgS/CO vs 1.884 lgS/CO,t=2.061,P=0.044);序贯治疗第24、36、48周两组HBsAg、HBeAg下降幅度差异均有统计学意义(1.330 vs 0.205,2.084 vs 0.258,1.972 vs 0.284,lg IU/ml;1.168 vs 0.455,1.363 vs 0.461,1.177 vs 0.447,lgS/CO)(t=2.238、p=0.049,t=2.619、P=0.025,t=2.278、P=0.048;t=2.273、P=0.043,t=3.415、P=0.001,t=2.271、P=0.049)。结论基线HBsAg、HBeAg以及其早期滴度下降均可预测HBeAg阳性的CHB患者应用核苷(酸)类似物序贯干扰素治疗的HBs(e)Ag消失/血清学转换率。 | 高媛娇 张璐 路遥 申戈 吴淑玲 郝红晓 常敏 胡蕾苹 李明慧 谢尧 | 2019 | 中华实验和临床病毒学杂志2019，33，5： | 6 |
| 5 | HBeAg阴性慢性乙型肝炎核苷(酸)类似物序贯干扰素治疗疗效的相关因素研究显示文摘目的研究HBeAg阴性慢性乙型肝炎(chronic hepatitis B,CHB)患者核苷(酸)类似物(nucleos(t)ide analogs,NA)序贯干扰素治疗疗效的影响因素。方法核苷(酸)类似物治疗的HBeAg阴性慢性乙型肝炎向PEG—IFNα-2α转换(序贯治疗),二者联合应用3个月后单独应用PEG-IFNα-2a治疗,PEG—IFNα-2a180μg每周1次皮下注射。监测患者序贯治疗前(基线)及序贯治疗的第12、24、36、48、72及96周的HBsAg含量和HBVDNA载量。结果共有26例HBeAg阴性CHB患者入组,有6例(23,1%)获得HBsAg消失/HBsAg血清学转换。获得HBsAg消失/HBsAg血清学转换组和未获得HBsAg消失/HBsAg血清学转换组这两组比较显示,获得HBsAg消失/HBsAg血清学转换组基线HBsAg含量为2.210log10IU/ml,显著低于(t=-4.252,P=0.000)非HBsAg消失患者的基线HBsAg含量(3.385log10IU/ml);序贯治疗72、96周以后两组HBsAg下降幅度均有显著性差异(3.511vs0.723log10IU/ml,4.291vs0.737loglnIU/ml)(t=6.712,P=0.000,t=13.391,P=0.000、0.000)。两组之间的年龄、性别、NA治疗时间均无统计学差异。12例(46.2%)获得SVR.获得SVR和未获得SVR组这两组比较显示,获得SVR组基线HBsAg含量为2.575log10IU/ml,显著低于(t=-4.319,P=0.000)非SVR患者(3.576log10IU/ml);序贯治疗的各时间点两组HBsAg下降幅度差异均有统计学意义(0.612vs0.088,1.192vs0.107,1.566vs0.167,1.817vs0.176,2.424vs0.193,2.188vs-0.014,log10IU/m1)(t=3.109、4.717、4.500、4.544、5.560、4.265,P=0.008、0.010、0.001、0.001、0.000、0.003)。两组之间的性别、NA治疗时间均无统计学差异,年龄差异有统计学意义(30.8vs39.9岁)(t=-2.747,P=0.011)。9例患者基线HBV DNA为阳性,序贯治疗后5例(55.6%)HBV DNA被抑制,HBV DNA被抑制的患者均在第12周时伴随HBsAg下降,但对随后HBsAg是否继续下降及转阴无影响。HBV DNA被抑制与未被抑制患者的年龄、性别、NA治疗时间、HBsAg基线含量,治疗过程中HBsAg下降幅度均无统计学差异。结论对于HBeAg阴性的CHB患者来说,基线HBsAg较低(2log10IU/ml水平)及其早期滴度大幅下降的核苷(酸)类似物序贯干扰素治疗患者较容易获得SVR;其中延长干扰素疗程更容易达到HBsAg消失/HBsAg血清学转换。 | 高媛娇 申戈 路遥 张璐 吴淑玲 郝红晓 常敏 胡蕾苹 华文浩 李明慧 谢尧 | 2018 | 中华实验和临床病毒学杂志2018，32，5： | 6 |
| 6 | HBsAg水平对ALT正常的HBeAg阳性慢性HBV感染者肝脏炎症发生的预测价值显示文摘目的探讨ALT正常且高病毒载量的HBeAg阳性慢性HBV感染者人群的肝炎发生情况及预测因素。方法本研究临床注册号为NCT04032275。回顾性选取2008年10月—2015年5月ALT正常、高病毒载量、HBeAg阳性的慢性HBV感染者183例,根据其肝穿刺活检结果分为肝炎组和无肝炎组。计量资料两组间比较采用t检验或Mann-Whitney U检验。计数资料两组间比较采用χ^(2)检验。使用单因素二元logistics回归分析预测因素,使用逐步后退法进行多因素二元logistics回归,使用受试者工作特征曲线(ROC)和约登指数分析截断值。结果肝炎组37例(20.2%),无肝炎组146例(79.8%),肝炎组的男性比例低于无肝炎组(45.9%vs 68.5%,χ^(2)=6.508,P=0.011)、AST高于无肝炎组[24(21.25~35.55)U/L vs 21.2(18.08~24.65)U/L,Z=-3.344,P=0.001]、HBsAg log值低于无肝炎组[4.4(4.28~4.49)vs 4.46(4.4~4.74),Z=-2.184,P=0.029]。HBsAg log值是肝炎发生的预测因素(OR=0.077,P=0.017)。HBsAg的截断值为33884.4 IU/mL。结论ALT正常、高病毒载量的HBeAg阳性患者中有20.2%肝脏存在炎症,HBsAg或许是肝脏炎症发生的预测因素。 | 曾湛 高媛娇 毕潇月 陈凤欣 邓雯 蒋婷婷 林妍洁 杨柳 李明慧 谢尧 | 2022 | 临床肝胆病杂志2022，38，5： | 5 |
| 7 | 低水平HBsAg患者肝组织HBsAg、HBcAg表达与血清HBsAg水平、HBVDNA载量的相关性显示文摘目的分析低水平HBsAg患者肝组织HBsAg、HBc Ag表达与血清HBsAg水平、HBV DNA载量的相关性,为低水平HBsAg患者的病情判断提供依据。方法选取2013年1月至2015年12月HBsAg水平低于1 400 IU/m L且高于0.05 IU/m L者作为研究对象,收集的63例低水平HBsAg患者均进行了肝组织活检。采用罗氏cobas e601全自动电化学发光免疫分析系统及配套试剂检测血清HBsAg,HBV DNA采用ROCHE公司全自动Ampli Prep/cobas Taq Man 48系统检测仪及配套试剂进行检测。结果 63例患者中,肝组织HBsAg表达阳性例数:阴性5例(7.94%)、+有47例(74.60%)、++有8例(12.70%)、+++有2例(3.17%)、++++有1例;而其HBc Ag表达阳性例数:阴性30例(47.62%)、+有28例(44.44%)、++有4例(6.35%)、+++有1例(1.59)、++++有0例。低水平HBsAg患者肝组织HBsAg表达与血清HBsAg水平通过spearman和kendall相关分析均呈显著正相关(spearman分析:r=0.261,P=0.039;kendall分析:r=0.217,P=0.036),而其与血清HBV DNA载量没有显著相关性;肝组织HBc Ag表达与血清HBsAg水平无显著相关性,而与血清HBV DNA载量通过spearman和kendall相关分析均有显著正相关性(spearman分析:r=0.305,P=0.015;kendall分析:r=0.259,P=0.017)。结论低水平HBsAg患者肝组织HBsAg表达与血清HBsAg水平呈显著正相关,而与HBV DNA载量无关;肝组织HBc Ag表达与血清HBV DNA载量有显著正相关性,而与血清HBsAg水平无关。 | 刘立 刘春云 王霖 刘云华 | 2017 | 实用医学杂志2017，33，21： | 4 |
| 8 | Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy显示文摘Objective To investigate the changes in the cytokine profiles of chronic hepatitis B(CHB)patients undergoing antiviral treatment.Methods Hepatitis B e antigen(HBeAg)-positive patients were treated with Pegylated interferon(PEGIFN)and entecavir(ETV).Clinical biochemistry and cytokines were detected at baseline and every 3 months.Results In all,200 patients completed 48 weeks of treatment,100 in the PEG-IFN group and 100 in the ETV group.During 3–6 months of treatment,compared with baseline,the PEG-IFN group showed a significant decrease in interferon-gamma(IFN-γ),interleukin-17 A(IL-17 A),interleukin-6(IL-6),interleukin-10(IL-10),and transforming growth factor beta(TGF-β)(P<0.001)and a significant increase in interferon-alpha 2(IFN-α2)(P<0.001).In the ETV group,IL-10 and TGF-β1 decreased significantly(P<0.001).After 3 months,the levels of IFN-α2,IL-17 A,and tumor necrosis factor-alpha(TNF-α)in the PEGIFN group were significantly higher than those in the ETV group(P<0.01).The levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).After 6 months,the levels of IFN-α2,IFN-γ,and TNF-αin the PEG-IFN group were significantly higher than those in the ETV group(P<0.01),while the levels of IL-6 and TGF-β3 were significantly lower than those in the ETV group(P<0.01).Compared with ETV,PEG-IFN had higher HBeAg and HBsAg disappearance rates.Conclusion During antiviral therapy,a change in the cytokine profile occurred;in the aspect of immune control and functional cure,PEG-IFN was significantly better than ETV. | LI Ming Hui LU Hui Hui CHEN Qi Qi LIN Yan Jie ZENG Zhan LU Yao ZHANG Lu DONG Jian Ping YI Wei XIE Yao | 2021 | Biomedical and Environmental Sciences2021，34，6： | 4 |
| 9 | 慢性乙型肝炎患者NK细胞功能与干扰素疗效相关性研究显示文摘目的 探讨慢性乙型肝炎(Chronic hepatitis B,CHB)患者外周血NK细胞频数及功能分子与干扰素α(Interferon-alpha,IFNα)疗效的相关性.方法 采集乙型肝炎病毒(Hepatitis B virus,HBV)慢性感染免疫清除(Immune clearance,IC)期经聚乙二醇干扰素α-2a(Peg-IFNα-2a)治疗患者在基线及治疗12和24周静脉全血,采用流式细胞仪检测外周血CD3-CD56+ NK细胞、CD56brightNK细胞和CD56dimNK细胞频数及NK细胞表面受体IFNAR2和NKp46的表达.血浆HBV DNA、HBsAg、HBeAg含量及肝功能由北京地坛医院检验科提供.结果 本实验共入组41例IC期经Peg-IFNα-2a治疗患者,包括21例应答不佳(Poor response,PG)患者和20例应答(Good response,GR)患者,结果显示:与基线比较,GR组CD3-CD56+NK细胞频数在治疗24周升高(11.74,5.69% - 18.15% vs 13.7,9.36% -20.18%,P〉0.05),在PR组同样升高(8.94,6.26% -14.15% vs 12.5,7.64%-16.55%,P〉0.05).GR组CD56brightNK细胞频数在治疗24周显著升高(9.49,6.2%-12.48%vs 12.98,7.75% -20.93%,P〉0.05),在PR组也同样显著升高(11.45,8.27% -19.13% vs 17.52,12.3% - 22.42%,P=0.0239).GR组NK细胞NKp46表达水平在治疗24周显著升高(90.55,83.8- 94.78 vs 93.8,92.28 - 96.4,P=0.0263),而PR组却未升高(95,90.6 - 96.15 vs 94.3,92.1-95.6,P〉0.05).GR组NK细胞NKp46high表达水平在治疗24周显著升高(12.4,8.58- 19.08 vs 39.3,23.15-49.3,P=0.0011),其升高幅度显著高于PR组(14.2,9.78 - 17.65 vs 27.58,19.13 -36.56,P=0.006).结论 慢性乙型肝炎患者经Peg-IFN-α-2a治疗后外周血CD3-CD56+ NK细胞和CD56bright NK细胞频数升高,对Peg-IFN-α-2a治疗应答患者NK细胞上NKp46表达上调,而且Peg-IFN-α-2a治疗使NKp46high表达显著上调,尤其在应答患者. | 屈晓晶 路遥 曹卫华 张英 冉崇平 齐天林 胡蕾苹 郝红晓 张璐 李明慧 谢尧 | 2017 | 中华实验和临床病毒学杂志2017，31，4： | 4 |
| 10 | ALT正常HBeAg阳性慢性HBV感染者免疫耐受期与不确定期临床特征显示文摘目的基于肝组织病理学检查,分析丙氨酸转氨酶(ALT)≤1倍正常值上限、HBeAg阳性慢性HBV感染者中,免疫耐受期与不确定期患者的临床病理特征。方法选取2012年7月至2018年5月在延安大学附属医院住院行肝活检的ALT正常、HBeAg阳性慢性HBV感染161例患者临床资料。其中免疫耐受期89例,不确定期72例。比较两组患者的一般资料、乙型肝炎血清标志物、HBV DNA、肝功能指标及肝脏硬度值(LSM)等差异。采用SPSS 26.0统计软件对数据进行分析。相关性分析采用Spearman相关性分析。结果不确定期患者占比44.7%(72/161)。免疫耐受期组患者的HBV DNA、HBsAg及HBeAg水平均高于不确定期组(P值均<0.001),而LSM值和抗-HBc水平低于不确定期组(P<0.01)。不确定期组患者中,肝组织炎症坏死分级(A)≥2为24例(33.3%),纤维化分期(F)≥2为28例(38.9%),其中A和F均≥2为16例(22.2%),A≥2和(或)F≥2共36例(50.0%)。HBV DNA>2×10^(7) IU/mL患者A≥2比例高于HBV DNA≤2×10^(7) IU/mL患者(55.6%比20.0%,P<0.01)。免疫耐受期组患者HBsAg与HBV DNA水平呈正相关(r=0.301,P<0.01),不确定期组患者HBsAg与HBV DNA水平,HBsAg与HBeAg水平,HBV DNA与HBeAg水平均呈正相关(r=0.513、0.732和0.650,P值均<0.001)。结论ALT正常、HBeAg阳性不确定期患者中部分肝组织已出现明显病理改变,有抗病毒适应证,须积极治疗。 | 辛杰晶 东冰 任丹丹 周路路 徐光华 刘娜 | 2022 | 中华临床感染病杂志2022，15，4： | 3 |
| 11 | Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy显示文摘Chronic hepatitis B virus(HBV)infection is a global public health problem,which can cause chronic hepatitis,liver cirrhosis,hepatocellular carcinoma(HCC),and other diseases.Antiviral therapy is the most critical measure to slow down the progression of chronic hepatitis B,prevent or delay cirrhosis,HCC,and other kinds of liver decompensation events.At present,the anti-hepatitis B virus drugs are mainly nucleoside(acid)analogues(NAs)and interferon.Each kind of antiviral drug has different effects on the clinical outcome of hepatitis B patients(such as HCC).In this paper,we discussed the biological characteristics,natural course and prognosis of HBV infection,the mechanism of HBV-related HCC,the effect of different antiviral drugs on patients’outcome,predictive biomarkers and model for HBV clinical outcome,predictors of sustained response and recurrence after withdrawal of antiviral therapy,consideration of expanding therapeutic indications and antiviral therapy,hoping to give a hand to the clinical diagnosis and treatment of HBV. | Huihui Lu Wei Yi Fangfang Sun Zhan Zeng Lu Zhang Minghui Li Yao Xie | 2021 | Biosafety and Health2021，3，4： | 1 |
| 12 | 核苷(酸)类似物序贯派格宾治疗慢性乙型肝炎实现功能性治愈的预测因素显示文摘目的 探究长期核苷(酸)类似物(NUC)抗病毒治疗后序贯派格宾(聚乙二醇干扰素α-2b)治疗的慢性乙型肝炎(CHB)患者实现功能性治愈的独立预测因素。方法 以青岛市多家医院2018年—2021年收治的CHB患者共162例为研究对象,所有患者均应用派格宾治疗至少48周,且在派格宾治疗前经过了1年及以上的NUC治疗。根据派格宾治疗48周时是否实现HBsAg阴转将入组患者分为功能性治愈组(79例)和未治愈组(82例),比较两组患者相关临床指标的差异。定量资料两组间比较采用两独立样本t检验和Mann-Whitney U秩和检验;定性资料两组间比较采用χ~2检验。相关性分析采用Spearman检验。单因素和多因素Logistic回归分析实现功能性治愈的独立预测因素。绘制相关变量的受试者工作特征曲线(ROC曲线),以曲线下面积(AUC)评估变量的预测准确度。结果 功能性治愈组患者的基线HBsAg显著低于未治愈组[21.63(3.33~157.60)IU/mL vs 794.70(336.10~1 185.34)IU/mL,Z=-8.869,P<0.001],派格宾治疗12周的HBsAg显著低于未治愈组[1.34(0.04~16.59)IU/mL vs 567.11(226.09~1 047.86)IU/mL,Z=-9.847,P<0.001],派格宾治疗24周的HBsAg显著低于未治愈组[0.01(0.00~0.34)IU/mL vs 304.79(89.24~772.23)IU/mL,Z=-10.474,P<0.001],派格宾治疗12周的HBsAg下降程度显著高于未治愈组[89.6%(57.5%~99.4%) vs 21.8%(2.0%~40.9%),Z=-7.926,P<0.001],派格宾治疗24周的HBsAg下降程度显著高于未治愈组[99.9%(99.0%~100.0%) vs 44.1%(20.6%~73.8%),Z=-9.593,P<0.05],基线HBeAg阳性率显著低于未治愈组(8.9%vs 25.3%,χ~2=7.652,P=0.006),基线HBV DNA>1000 IU/mL的比例显著低于未治愈组(0 vs 8.4%,χ~2=5.073,P=0.024),基线总胆红素显著低于未治愈组[12.60(10.12~15.93)μmol/L vs 15.50(11.80~24.10)μmol/L,Z=-3.611,P<0.001],治疗12周的AST显著高于未治愈组[47.00(34.00~68.00)U/L vs 41.00(30.00~56.50)U/L,Z=-2.031,P=0.042],治疗12周AST>2倍正常值上限比例显著高于未治愈组(16.5%vs 4.8%,χ~2=5.835,P=0.016)。多因素Logistic回归分析显示,基线HBsAg(OR=0.996,95%CI:0.995~0.997)、派格宾治疗12周HBsAg(OR=0.990,95%CI:0.986~0.994)、派格宾治疗24周HBsAg(OR=0.983,95%CI:0.975~0.991)、基线总胆红素(OR=0.885,95%CI:0.826~0.949)为功能性治愈的独立预测因素(P值均<0.05)。基线HBsAg对应的AUC为0.904,最佳界值为118.24 IU/mL;派格宾治疗12周HBsAg对应的AUC为0.948,最佳界值为73.74 IU/mL;派格宾治疗24周HBsAg对应的AUC为0.975,最佳界值为11.01 IU/mL;基线总胆红素对应的AUC为0.664,最佳界值为19.9μmol/L。结论 NUC序贯派格宾治疗CHB时基线HBsAg、派格宾治疗12周HBsAg、派格宾治疗24周HBsAg以及基线总胆红素水平是派格宾治疗48周时患者实现功能性治愈的独立预测因素。 | 臧海洋 李伟娜 刘守胜 周永 辛永宁 | 2023 | 临床肝胆病杂志2023，39，2： | 1 |
| 13 | Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients显示文摘Hepatitis B surface antigen(HBsAg)clearance is considered as functional cure in patients with chronic hepatitis B(CHB).This study aimed to assess the durability of HBsAg clearance achieved by interferon-based therapies in patients with CHB who were originally positive for hepatitis B envelope antigen(HBeAg).In this prospective study,HBeAg-positive CHB patients with confirmed HBsAg loss under interferon-based therapies were enrolled within 12 weeks from end of treatment and followed up for 48 weeks.Virological markers,biochemical indicators,and liver imaging examinations were observed every 3–6 months.Sustained functional cure was analysed as primary outcome.Factor associated with sustained HBsAg loss or reversion was also investigated.The rate of HBsAg loss sustainability was 91.8%(212/231).Patients receiving consolidation treatment for 12–24weeks or≥24 weeks had higher rates of sustained HBsAg negativity than those receiving consolidation treatment for<12 weeks(98.3%and 91.2%vs.86.7%,P=0.068),and the former groups had significantly higher anti-HBs levels than the later(P<0.05).The cumulative incidence of HBsAg reversion and HBV DNA reversion was 8.2%and 3.9%,respectively.Consolidation treatment of≥12 weeks[odd ratio(OR)3.318,95%confidence interval(CI)1.077–10.224,P=0.037)was a predictor of sustained functional cure,and HBeAg-positivity at cessation of treatment(OR 12.271,95%CI 1.076–139.919,P=0.043)was a predictor of HBsAg reversion.Interferon-alpha induced functional cure was durable and a consolidation treatment of≥12–24 weeks was needed after HBsAg loss in HBeAg-positive CHB patients. | Minghui Li Fangfang Sun Xiaoyue Bi Yanjie Lin Liu Yang Yao Lu Lu Zhang Gang Wan Wei Yi Linqing Zhao Yao Xie | 2022 | Virologica Sinica2022，37，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员